4.4 Article

Evaluation of virulence factors of Candida albicans isolated from HIV-positive individuals using HAART

Journal

ARCHIVES OF ORAL BIOLOGY
Volume 66, Issue -, Pages 61-65

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.archoralbio.2016.02.004

Keywords

Candida albicans; HIV; virulence factors; Exoenzyme

Funding

  1. CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)
  2. CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)
  3. FAPEMIG (Fundacao de Amparo a Pesquisa do estado de Minas Gerais) [APQ-00464-11]

Ask authors/readers for more resources

The colonization by Candida species is one of the most important factors related to the development of oral candidiasis in HIV-infected individuals. The aim of the study was to evaluate and discuss the phospholipase, proteinase, DNAse and haemolytic activities of Candida albicans isolated from the oral cavity of HIV individuals with high efficiency antiretroviral therapy. Seventy-five isolates of C. albicans obtained from saliva samples of patients with HIV and 41 isolates from HIV-negative individuals were studied. Haemolytic activity was determined in Sabouraud dextrose agar plates containing 3% glucose and 7% sheep red cells. Culture medium containing DNA base-agar, egg yolk, and bovine albumin were used to determine DNase, phospholipase and proteinase activities, respectively. All isolates from the HIV patients group had haemolytic activity, 98% showed phospholipase activity, 92% were positive for proteinase and 32% DNAse activity. Regarding the group of individios HIV negative, all 41 isolates presented hemolytic activity, 90.2% showed phospholipase and proteinase activity and 12.2% were positive for DNAse. The phospholipase activity was more intense for the group of HIV positive individuals. DNase production was more frequently observed in the group of HIV-positive individuals. The percentage of isolates having DNAse activity was also significantly different between the groups of patients not using any antiretroviral therapy, those using transcriptase inhibitors and those using transcriptase inhibitor and protease inhibitor in combination. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available